Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

amifampridine phosphate

FIRDAPSE

amifampridine phosphate (FIRDAPSE) is a voltage-gated potassium channel blocker. Associated with CATALYST PHARMACEUTICALS, INC.. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 6
News articles 0
Drug details — amifampridine phosphate
US status
approved
Class
—
Route
ORAL
Patents
20
Programs
6
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

amifampridine phosphate (FIRDAPSE) is a voltage-gated potassium channel blocker. Associated with CATALYST PHARMACEUTICALS, INC.. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN amifampridine phosphate
Brand FIRDAPSE
Mechanism Voltage-gated potassium channel blocker
Target Voltage-gated potassium channel
Route ORAL
Formulation TABLET
Originator CATALYST PHARMACEUTICALS, INC.

Mechanism of action

Voltage-gated potassium channel blocker

Primary target: Voltage-gated potassium channel

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. Amifampridine Phosphate Phase 3 · CATALYST PHARMACEUTICALS · Lambert Eaton Myasthenic Syndrome
  2. Amifampridine Phosphate Phase 3 · CATALYST PHARMACEUTICALS · Myasthenia Gravis, Generalized
  3. Amifampridine Phosphate Phase 3 · CATALYST PHARMACEUTICALS · Myasthenia Gravis, MuSK
  4. amifampridine phosphate Phase 3 · CATALYST PHARMACEUTICALS · Myasthenic Syndromes, Congenital
  5. Amifampridine Phosphate Phase 2 · CATALYST PHARMACEUTICALS · Muscular Atrophy, Spinal
  6. Amifampridine Phosphate 10 MG Oral Tablet Phase 2 · CATALYST PHARMACEUTICALS · Spinal Muscular Atrophy Type 3

Related & competitor drugs

Browse all drugs
  1. dalfampridine Voltage-gated potassium channel blocker
  2. amifampridine Nervous system (N07)
  3. guanidine hydrochloride Voltage-gated potassium channel blocker
  4. fampridine Nervous system (N07)

Related patents

Browse patents CATALYST PHARMACEUTICALS, INC. patent hub

  1. US 11806421

    Porous-cellulose particles and production method thereof, and cosmetic

    Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11384062

    Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11020326

    Hollow particles and cosmetic

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10314769

    Organic-inorganic composite particles and cosmetic product

    Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10143636

    Porous silica particle and cleansing cosmetic

    Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9889072

    Porous silica particle, method for producing the same, and cleansing cosmetic containing the same

    Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9855195

    Dental curable composition

    Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9808407

    Porous silica particle, method for producing the same, and cosmetic containing the same

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9327258

    Porous silica-based particles having smooth surface, method for production thereof and cosmetic comprising such particles

    Expires Mon Apr 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9254274

    Method of treating Tourette'S disorder with GABA-aminotransferase inactivators

    Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9011888

    Organic-inorganic composite particles, process for producing the same, dispersion containing the particles, and cosmetic containing the particles

    Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8969413

    Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid

    Expires Mon Feb 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8455564

    Dental composition and composite resin

    Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8440739

    Dental composition and composite resin

    Expires Mon May 09 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 8436078

    Dental composition and composite resin

    Expires Mon May 02 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 8338107

    Method for producing polymers having a preselected activity

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8182860

    Dental filler

    Expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8048906

    Optically pure and enriched isomers of chelating ligands and contrast agents

    Expires Mon Oct 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7981513

    Dental filler

    Expires Mon Jul 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7727602

    Recording sheet with ink receptive layer and coating liquid for forming ink receptive layer

    Expires Mon May 27 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is amifampridine phosphate?

amifampridine phosphate (FIRDAPSE) is a voltage-gated potassium channel blocker. Associated with CATALYST PHARMACEUTICALS, INC.. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for amifampridine phosphate?

FIRDAPSE is a marketed brand name for amifampridine phosphate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of amifampridine phosphate?

amifampridine phosphate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.